+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07234058

Phase II Trial of Cemiplimab With or Without Fianlimab Plus Pemetrexed-Platinum Chemotherapy for Patients With Untreated Unresectable Pleural Mesothelioma

Led by Intergroupe Francophone de Cancerologie Thoracique · Updated on 2026-08-11

126

Participants Needed

37

Research Sites

69 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial focuses on patients with treatment-naive, unresectable malignant pleural mesothelioma PM. It is a multicenter, phase IIR, randomized study evaluating two immunotherapy combinations alongside chemotherapy. The purpose is to assess the activity and safety of combining anti-LAG3 and anti-PD-1 immunotherapies with pemetrexed and platinum-based chemotherapy, providing new treatment options for this condition. Participants are randomly assigned to one of two treatment arms. One group receives cemiplimab 350 mg every 3 weeks for up to 24 months, combined with pemetrexed and a platinum agent cisplatin or carboplatin for six 21-day cycles. The other group receives cemiplimab 350 mg plus fianlimab 1600 mg every 3 weeks for up to 24 months, with the same chemotherapy regimen. Treatment continues until disease progression, unacceptable side effects, withdrawal, or a maximum of 2 years of immunotherapy. During the study, participants undergo regular assessments including imaging scans to measure tumor response, safety evaluations, and quality of life questionnaires. Researchers monitor progression-free survival, overall survival, and treatment tolerance throughout the treatment and for up to two years after starting therapy. Follow-up continues after treatment ends to track long-term outcomes and safety.

CONDITIONS

Brief Title

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Research Team

C

Contact IFCT

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here